Evidence map›Paper›PMID 41159846›Full record

ArticleCPT: pharmacometrics & systems pharmacology2025

QSP-Copilot: An AI-Augmented Platform for Accelerating Quantitative Systems Pharmacology Model Development.

Anuraag Saini, Ali Farnoud

Abstract read
In one paragraph

Article in CPT: pharmacometrics & systems pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. New approach methodologies (NAMs) for preclinical and translational evaluation of mRNA-lipid nanoparticle (LNP) therapeutics.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Review
  2. Structured Schemas for Provenance-Rich, LLM-Assisted QSP Model Calibration.CPT: pharmacometrics & systems pharmacology · 2026
    Article
  3. Article
  4. Quantitative Systems Pharmacology Modeling Amid the Rise of Agentic AI.CPT: pharmacometrics & systems pharmacology · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Anuraag SainiBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.ORCID 0000-0002-8598-2327
Ali FarnoudBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.ORCID 0000-0002-9298-5497

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Quantitative Systems Pharmacology (QSP) is a powerful approach to provide decision-making support throughout the drug development process. QSP comes with many challenges in model development, validation, and applications. Traditional QSP workflows are limited by slow knowledge integration, labor-intensive model construction, inconsistent validation practices, and restricted scalability. In this work, we introduce QSP-Copilot, the first end-to-end AI-augmented solution designed to improve QSP modeling workflows by integrating a multi-agent system utilizing large language models (LLMs). QSP-Copilot provides modular support from project scoping and model structuring to model evaluation and reporting. Through the automation of routine tasks, QSP-Copilot reduces model development time by approximately 40% and improves methodological transparency through systematic documentation of literature sources and modeling assumptions. We demonstrate QSP-Copilot's application for two rare diseases of blood coagulation and Gaucher disease. In the blood coagulation case, automated extraction from ten peer-reviewed articles yielded 179 biological entity interaction pairs; out of these, only 105 unique mechanisms were retained after standardization. For Gaucher disease, screening nine articles produced 151 pairs, which were consolidated into 68 distinct biological interactions following the same post-processing workflow. The extraction precision for blood coagulation and Gaucher disease is 99.1% and 100.0%, respectively. QSP-Copilot extractions can be incorporated into effect diagrams with minimal expert filtering, significantly reducing the manual curation burden. The integration of AI-augmented workflows like QSP-Copilot represents a pivotal shift toward enhanced scalability and impact for QSP across the drug development pipelines, especially in disease areas where biological knowledge is sparse, such as rare diseases.

Indexed as

Artificial IntelligenceDrug DevelopmentModels, BiologicalSystems BiologyHumansWorkflowagentic workflowsartificial intelligence (AI)knowledge integrationlarge language models (LLMs)QSP‐copilotquantitative systems pharmacology (QSP)rare diseases

Identifiers

PMID41159846
PMCPMC12625087

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.